All About Tumor Lysis Syndrome in DLBCL
Event Description
Discover crucial insights about tumor lysis syndrome in diffuse large B-cell lymphoma (DLBCL) in this upcoming webinar, presented by a leading lymphoma expert. This session will delve into the causes, risk factors, and management strategies of tumor lysis syndrome specific to DLBCL. Register now to enhance your understanding and engage with an expert on this important topic.
Schedule & Agenda
Cynthia introduces the agenda and our featured speaker Dr. Roshan Asrani
Cynthia introduces the agenda and our featured speaker Dr. Roshan Asrani
Dr. Asrani talks about causes, risk factors, and management strategies of tumor lysis syndrome specific to DLBCL
Dr. Asrani talks about causes, risk factors, and management strategies of tumor lysis syndrome specific to DLBCL
Come with your questions and we will answer them!
Come with your questions and we will answer them!
Speakers & Moderators
Cynthia is a newborn ICU nurse by trade that has spent the last six years in the medical device industry educating nurses and doctors about devices that are new to their facility. In her spare time she enjoys hiking, traveling the world with her family, and creating Halloween animatronics for her annual front yard display. She has a passion for life-long learning and enjoys sharing what she learns with the people around her.
Dr. Roshan Asrani is an Assistant Professor of medicine for the Division of Hematology & Medical Oncology at the Icahn School of Medicine at Mount Sinai. He also sees and treats patients through the lymphoma and CLL program at Tisch Cancer Institute
Have Any Questions?
Thank you for your interest in the event. If you have any questions, we would love to help!
Feel free to give us a call or send us a message below.
Get In Touch With Us
1-800-709-1113
Support@healthtree.org
Get the latest thought leadership on your Blood Cancer delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.